NCT03697707View on ClinicalTrials.gov

Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia in Remission
Interventions
BIOLOGICAL

DCP-001

allogeneic dendritic cell vaccine

Trial Locations (10)

Unknown

Helsinki University Hospital, Helsinki

Universitats Klinikum Bonn, Bonn

Universitats Klinikum Leipzig, Leipzig

Universitätsmedizin Mainz, Mainz

VUmc, Amsterdam

UMCG, Groningen

Maastricht University Medical Centre, Maastricht

Haukeland universitetssjukehus, Bergen

Uppsala University Hospital, Uppsala

D- 40479

Marien Hospital, Düsseldorf

Sponsors

Lead Sponsor

Mendus
All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

lead

Mendus

INDUSTRY

NCT03697707 - Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia | Biotech Hunter | Biotech Hunter